Inpatient Management of Opioid Use Disorder: Methadone

Authors: Diana Coffa, MD, Kristin Harter, PharmD, Ben Smith, MD, Hannah Snyder, MD, Sarah Windels

Advisors: Soraya Azari, MD, Jadine Cehand NP, CNS, Curtis Geier, PharmD, Michelle Geier, PharmD, Corinna Gamez, MD, Greg Greenberg, MD, Andrew Herring, MD, Tamara Lenhoff, PharmD, David Kan, MD, Kelly Pfeiffer, MD, Brad Shapiro, MD, Scott Steiger, MD, Becky Tsui, MD, Barry Zevin, MD

Disclaimer: These clinical practice guidelines do not set a standard of care, rather they are an educational aid to practice. They do not set a single best course of management, nor do they include all available management options. They were developed by an interdisciplinary team based on published evidence and expert opinion; as the literature develops best practices may change. They should never be used as a substitute for clinical judgement. Individual providers are responsible for assessing the unique circumstances and needs of each case. Adherence to these guidelines will not ensure successful treatment in every situation. This information is intended for healthcare providers and subject matter experts, it is not intended for use by patients and the general population.

This guideline applies to patients in inpatient medical settings. If any of the following points are different for pregnant patients, it is noted in each segment of the following document.
Goal of Treatment:

- COWS (Clinical Opioid Withdrawal Score – See Appendix A) of 5 or less for a period of 24 to 36 hours
- Elimination of drug hunger or cravings
- No sedation or respiratory depression from medication
- If patient uses illicit opioids while on methadone, patient should not feel substantially intoxicated

Monitoring:

- COWS and the Ramsey sedation scale are used to monitor a patient’s response to methadone. COWS can be done by a provider or RN trained in the assessment, sedation scale can be done by RN.
- In general, COWS should be checked once prior to methadone initiation and Ramsey assessments should be done 1 hour after each dose for newly starting patients or for those patients who are being re-titrated to a maintenance dose. Sedation checks can be stopped when dosing is stabilized.
- Pregnancy Only: Fetal monitoring beyond what is necessary for initial fetal evaluation is not necessary solely for methadone administration unless ordered by provider.

Patients on outpatient methadone:

- Provider MUST contact patient’s outpatient opioid treatment program (methadone clinic) to confirm dosing and last administration.
- Continue the patient’s current dose, after checking that inpatient medications do not change metabolism or prolong QTC, that the patient is not sedated, and that the patient is not intoxicated.
- If patient has pain requiring any opioids, short-acting opioids for pain management may be added. Splitting patient’s maintenance methadone dose for mild acute pain may also be considered. Maintenance methadone alone is not sufficient to treat moderate pain.
- If patient’s methadone clinic cannot be reached, provider should follow methadone-naïve dosing algorithm below to control symptoms until patient’s clinic can be reached.
- If patient has missed outpatient dosing, please discuss dose decrease plans with patient’s methadone clinic provider. If the dose is confirmed by the clinic but the clinic provider cannot be reached, one approach is to give patient’s full dose if 1-2 days are missed, half the dose if 3-4 days are missed, and treat as a new start if 5 or more days are missed (step 5 below). In this case, provider may re-titrater patient dose up based on sedation and withdrawal. However, it is strongly recommend to discuss any missed dose adjustments with the methadone clinic as these are high risk situations.
- Naloxone must also be ordered by the provider as a PRN for signs of overdose (0.1 mg IV/IM q 1 to 2 minutes PRN RR < 8/min or Ramsey sedation scale ≥ 5, x 3 doses).
### Patients who are considering starting methadone

1. **Determine clinical indication for methadone therapy:**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Contraindications</th>
<th>Caution</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Opioid use disorder, severe, with or without comorbid chronic pain <strong>and</strong>&lt;br&gt;- Desire for methadone treatment to assist with cessation or reduction in use</td>
<td>- Allergy to methadone&lt;br&gt;- Respiratory depression&lt;br&gt;- Ramsey sedation scale ≥ 4</td>
<td>- QTc&gt;500&lt;br&gt;- Recent use of benzodiazepines, alcohol, or other sedatives&lt;br&gt;- Liver disease&lt;br&gt;- Comorbid alcohol withdrawal&lt;br&gt;- <strong>Pregnancy only</strong>: induction may occur at outpatient clinic or inpatient under obstetric team guidance&lt;br&gt;<strong>If the patient falls under the “caution” category, call the UCSF Substance Use Warmline (855.300.3595 or <a href="https://tinyurl.com/yc75cmx6">https://tinyurl.com/yc75cmx6</a>) or your local addiction specialists.</strong></td>
</tr>
</tbody>
</table>

2. **Discuss options with patient and obtain patient preference for methadone vs. buprenorphine** (see Appendix B – Non-pregnancy Decision Guide; **Pregnancy Only**: See Appendix C – Pregnancy Only Decision Guide). In the inpatient setting clinicians can legally order buprenorphine or methadone if the patient is admitted primarily for another medical reason.\(^1\)\(^2\) Prior to starting methadone, ensure that there is a local methadone clinic that will be able to enroll your patient in their program.

---


---

For questions or concerns, please consider consulting the UCSF Clinician Consultation Center Substance Use Warmline at (855) 300-3595 Monday through Friday, between 9 a.m. and 8 p.m EST. or [https://tinyurl.com/yc75cmx6](https://tinyurl.com/yc75cmx6)
3. Prior to induction:
   - Verify DSM 5 criteria for opioid use disorder
   - Check baseline EKG for QTc, CURES report (https://cures.doj.ca.gov), urine tox screen, urine pregnancy test. Of note, CURES will not show methadone dispensed at a methadone clinic/opioid treatment program. 
     
     **Pregnancy Only:** also check baseline maternal vital signs, NST as indicated, and a urine tox (utox can only be performed after patient verbal consent)
   - If a patient is experienced mixed alcohol and opioid withdrawal, be very cautious and consult with experts to determine which pathology predominate as the combination of benzodiazepines and opioids can be high risk
   - Naloxone must also be ordered by provider as a PRN for signs of overdose (0.1 mg IV/IM q 1 to 2 minutes PRN RR < 8/min and difficult to arouse or Ramsey sedation scale ≥ 5, x 3 doses).
   - Consider adjunctive medications to help to control withdrawal symptoms, prior to starting and during induction. Check for contraindications and drug-drug interactions before beginning any new medications. Of note, this will lower COWS scores therefore may prolong the induction.
     - Acetaminophen 650 mg PO 6 four times daily PRN pain
     - Clonidine 0.1 -0.3 mg PO q6-8 hours prn w/d symptoms (NTE 1.2 mg/24 hours, hold if BP<100/70)
     - Diphenhydramine 25-50 mg, PO three times daily prn insomnia/anxiety
     - Ibuprofen 400-800 mg, PO four times daily prn pain (**Pregnancy Only: Ibuprofen is contraindicated**)
     - Loperamide 4 mg PO x 1 initially, then 2 mg prn each additional loose stool (NTE 16 mg/24 hours)
     - Ondansetron 4 mg PO every 6 hours PRN nausea
     - Melatonin 3 mg qHS PRN insomnia
     - Trazodone 50 mg qHS PRN insomnia
     - DO NOT ORDER benzodiazepines as standard PRN adjunctive therapy.

4. Methadone dosing considerations:
   - Peak concentration of methadone is ~3.5 hours after dose received and onset of action is 30 minutes to 1 hour after dose is received, so provider or RN per provider order must evaluate for sedation and withdrawal symptoms via COWS assessment 30 minutes and 4 hours after each dose
   - Steady state is reached after ~4.5 days at same dose (levels continue to rise for several days after dose increase)
   - The initial dose depends on patient (standard is 10 to 30 mg), as the severity of withdrawal does not reliably indicate the level of tolerance. Dosing is at provider’s discretion, but provider may contact an expert, such as at the Substance Use Warmline or local opioid treatment program
   - If patient is not interested in methadone maintenance therapy and only wants withdrawal treatment while hospitalized, do not exceed 40 mg and taper such that patient receives 20 mg or less on day of discharge. However, this medically assisted withdrawal (detox) is discouraged due to high rates of relapse. Patients should be strongly encouraged to up-titrate dose and engage in maintenance treatment.
   - In patients who are NPO, methadone can be administered via NG tube, as a sublingual liquid, or IV. Discuss dosing intervals and IV vs PO bioavailability with pharmacy prior to use.
5. Methadone naive patient dosing algorithm

**DAY 1**

- Prior to first dose: check COWS and Ramsay score, then if no sedation and regardless of presence of withdrawal, provider may order 10 to 30 mg of methadone.
- 1 hour after first dose: provider or RN per provider order must check Ramsay.
- 4 hours after first dose: if patient endorsing withdrawal or cravings, check Ramsay. If no sedation, may order an additional 5 - 10 mg.
- 1 hour after second dose: provider or RN per provider order must check Ramsay.
- 4 hours after second dose: if withdrawal or cravings are present, check Ramsay. If no sedation and patient has not reached 40 mg for day 1, provider may order an additional 5 - 10 mg dose.
- 1 hour after third dose: provider or RN per provider order must check Ramsay.
- No PRN methadone orders are to be written.
- If at any point patient experiences sedation, additional methadone doses are not to be ordered and subsequent doses should be held or decreased in consultation with pharmacy.
- Total methadone dose NTE 40 mg on day 1 (first 24 hours).
- Provider may order adjunctive medications to treat withdrawal symptoms (see Adjunctive Medication above).
- Have Social Work provide a list of Opiate Treatment Programs (OTP) and send referral to program of patient’s choice.
  - **Pregnancy Only:** Confirm capacity for a new pregnant patient before referring.

**DAY 2**

- Prior to first dose: provider or RN per provider order must check Ramsay.
- First dose: If no sedation and no withdrawal or cravings, provider should order methadone daily dose equal to the total dose of methadone administered on day 1 (first 24 hours). If withdrawal or craving is present and there is no sedation, then provider may order total daily dose from day 1 + 10 mg as a single morning dose.
- 1 hour after first dose: provider or RN per provider order must check Ramsay.
- 4 hours after first dose: if withdrawal or cravings are present, check Ramsay. If no sedation, provider may order another one-time 5 - 10 mg dose as long as the daily limit of 50 mg has not been reached.
- 1 hour after second dose: provider or RN per provider order must check Ramsay.
- If somnolence or respiratory depression is present at any point, hold additional methadone doses and decrease next day’s dose in consultation with pharmacy.
- Total methadone dose NTE 50 mg on day 2.

**DAY 3**

- Prior to first dose: provider or RN per provider order must check Ramsay.
- First dose: If no sedation and no withdrawal or cravings, provider should order methadone daily dose equal to the total dose of methadone administered on day 2. If withdrawal or craving is present and there is no sedation, then provider may order total daily dose from day 2 + 10 mg as a single morning dose.
- 1 hour after first dose: provider or RN per provider order must check Ramsay.
- 4 hours after first dose: if withdrawal or cravings are present, check Ramsay. If no sedation, provider may order another one-time 5 - 10 mg dose as long as the daily limit of 60 mg has not been reached.
- 1 hour after second dose: provider or RN per provider order must check Ramsay.
- If any somnolence or respiratory depression is present, hold additional doses and decrease next day’s dose in consultation with pharmacy.
- Total methadone dose NTE 60 mg on day 3.

For questions or concerns, please consider consulting the UCSF Clinician Consultation Center Substance Use Warmline at (855) 300-3595 Monday through Friday, between 9 a.m. and 8 p.m EST. or [https://tinyurl.com/yd4ymyx6](https://tinyurl.com/yd4ymyx6)
## Subsequent hospital days

- It is generally best to hold dose steady for 5 days before further increase, due to pharmacokinetics.
- Provider must actively reinforce plans for maintenance therapy and work on discharge plans.
- Provider or RN per provider order should continue to check a Ramsay 1 hour after each dose of methadone.
- If any evidence of somnolence or respiratory depression occurs, provider should decrease patient’s daily dose in consultation with a consult service if needed.
- In patients who are NPO, methadone can be administered via NG tube or as a sublingual liquid.
- Further titration at approximately 10 mg every 5 days can continue based on ongoing cravings or withdrawal.

## Discharge planning

- Social work or provider should confirm OTP’s intake availability and details with their intake coordinator
- Some OTPs require that if patient is to discharge on a weekend or holiday, they will need to be transported to the clinic on a non-holiday weekday to complete the intake process prior to hospital discharge
- Skilled nursing facilities (SNFs) that are not classified as hospitals can only keep patients on methadone if patients are already enrolled in an outpatient methadone program—discuss these details with the SNF early in the process
- You cannot prescribe methadone on discharge. The patient will need to go to the designated OTP, usually early the day after discharge. The OTP will often request that you fax a discharge summary prior to the patient’s arrival.
- Prescribe naloxone on discharge as a prn medication for signs/symptoms of overdose and also consider PREP/PEP if indicated for HIV prevention

## Other Dosing Considerations

- **Replacing Vomited Doses:**
  - If tablets are used and full dose is visible in emesis, can consider replacing the entire dose
  - If emesis occurs < 15 minutes after administration, consider replacing 50% of dose
  - If emesis occurs > 15 minutes after administration, do NOT replace the dose, rather, check sedation and withdrawal symptoms 4 hours after and re-titrater the dose. Provider may order a 5-10 mg one time dose at that time if needed.
- **Addressing Overdose:**
  - Overdose is marked by obtundation, apnea, respiratory failure, and hypoxia.
  - RN to call provider and start oxygen for RR < 12, O2 saturation < 95%, and/or change in mental status.
  - Administer naloxone per provider order for RR < 8 or sedation scale ≥ 5.
  - Hold all additional opioid doses and consult a local addiction expert or the Substance Use Warmline
- **Split Dosing:**
  - Split dosing may be necessary for patient with acute or chronic severe pain.
  - **Pregnancy Only:** As gestational age increases, plasma levels of methadone change secondary to a decrease in half-life and an increase in clearance and volume of distribution. This generally occurs during the second and third trimester. As such, provider may strongly consider splitting the daily methadone dose to an AM and PM dose if the patient experiences withdrawal symptoms or cravings at night.
Drug Interactions
Some common drugs may have pharmacokinetic or synergistic interactions with methadone. The methadone dose may require adjustment. Please consult with clinical pharmacist for more complete list of interactions.

- Drugs that may INCREASE methadone concentration or effect (okay to use, but monitor the patient): azole antifungals, some SSRI’s, tricyclic antidepressants, erythromycin, ciprofloxacin, quetiapine
- Drugs that may DECREASE methadone concentration/effect: rifampin, many antiretrovirals, phenytoin, carbamezapine
- **CAUTION** co-administration of CNS depressants such as benzodiazepines may lead to increased sedation and respiratory depression, while co-administration of naltrexone or buprenorphine may lead to precipitated withdrawal

Breastfeeding Guidelines:
Methadone maintenance for opioid use disorder is not a contraindication for breastfeeding. Patients taking methadone for opioid use disorder who are not currently abusing other substances and who wish to breastfeed should be encouraged to regardless of the methadone dose. Current evidence shows that breastfeeding while on methadone maintenance is beneficial to neonates with neonatal abstinence syndrome (NAS). Neonates receiving breast milk from these patients experience lower NAS scores, require less pharmacologic treatment such as morphine, and have shorter lengths of hospital stay.
Quick Guide: Methadone Starts in the Hospital

Day 1: max daily dose 40 mg methadone
- Check COWS and Ramsay
- Administer 10-30mg methadone
- Recheck Ramsay in 1 hour

After 4 hours
- If endorsing withdrawal/cravings, check Ramsay
- If no sedation, order additional 5 - 10 mg dose
- Recheck Ramsay in 1 hour

After 4 hours
- If endorsing withdrawal/cravings, check Ramsay
- If no sedation and not at max daily dose, order additional 5-10 mg dose
- Recheck Ramsay in 1 hour

Day 2: max daily dose 50 mg methadone
- Check Ramsay, proceed if no sedation
- Give total daily dose from day 1 as single dose
- Recheck Ramsay in 1 hour

After 4 hours
- If endorsing withdrawal/cravings, check Ramsay
- If no sedation, order additional 5 - 10 mg dose
- Recheck Ramsay in 1 hour

After 4 hours
- If endorsing withdrawal/cravings, check Ramsay
- If no sedation and not at max daily dose, order additional 5-10 mg dose
- Recheck Ramsay in 1 hour

Ramsay sedation score:
1. Anxious/restless
2. Cooperative/oriented/tranquil
3. Response to commands
4. Brisk response to stimulus
5. Sluggish response to stimulus
6. No response to stimulus

Testing prior to first dose:
- Urine toxicology
- EKG for QTc interval
- Urine pregnancy test (PRN childbearing potential)
- DSM 5 criteria for opioid use disorder
- CURES report
- Consider HIV, HepB, HepC testing

Pregnancy:
- non-stress test or fetal heart tones as indicated

Contraindications/cautions:
- Call experts as needed, may still start with support
- Allergy to methadone
- Respiratory depression
- Ramsay sedation scale ≥ 4
- QTC > 500
- Recent use of benzodiazepines, alcohol, or other sedatives
- Severe liver disease
- Comorbid alcohol withdrawal

Initial dose selection:
Anywhere from 10-30 mg may be selected. Patients should be dosed according to tolerance (expect lower tolerance with non-daily users, oral hydrocodone, smoked opium users, etc). May use morphine equivalent calculator as a guide. Withdrawal severity is not well correlated with tolerance.

Discharge prescriptions:
- Methadone may not be prescribed for opioid use disorder. Must be administered in methadone clinic.
- Naloxone 4 mg/0.1 ml intranasal PRN opioid overdose. Spray 0.1 ml into one nostril, call 911, if no response in 2-3 minutes repeat with second device in additional nostril. #1 pack of 2, 3 refills
- Consider pre-exposure HIV prophylaxis

Day 3: Follow instruction for day 2 above, but with first dose being total daily dose from day 2. Max dose on day 3 is 60 mg.
Subsequent days: Do not increase dose for 5 days. Can increase by 10 mg every 5 days subsequently.

Somnolence/respiratory depression: All patients should have order for naloxone 0.1 mg IV/IM q 1 to 2 minutes PRN RR < 8/min and difficult to arouse or Ramsay sedation scale ≥ 5, x 3 doses. Caution: the use of additional opioids or benzodiazepines during this time can increase risk of somnolence/respiratory depression, and should be avoided if possible. If RR < 8 or Ramsay > 2 at any time, do not give additional methadone. Consider dose decrease, and consult with experts.

Adjunctive meds: The following can be prescribed prn for symptoms of withdrawal (check for contraindications and drug-drug interactions).
- Acetaminophen 650 mg PO q 6 hours daily PRN pain
- Clonidine 0.1-0.3 mg PO q 6-8 hours PRN w/d symptoms (NTE 1.2 mg/day, hold if BP < 100/70)
- Diphenhydramine 25-50 mg, PO q 8 hours PRN insomnia/anxiety
- Loperamide 4 mg PO initially, then 2 mg PRN each additional loose stool (NTE 16 mg/24 hours)
- Ondansetron 4 mg PO q 6 hours PRN nausea
- Trazodone 50 mg PO qhs PRN insomnia
- Melatonin 3 mg PO qhs PRN insomnia

For clinical questions:
UCSF Substance Use Warm-line 855-300-3595 or https://tinyurl.com/yd4ymyx6 (M-F 9am-8pm ET)
**Clinical Opioid Withdrawal Score (COWS)**

For each item, write in the number that best describes the patient’s signs or symptom. Rate only the apparent relationship to opiate withdrawal. For example: If heart rate is increased because the patient was jogging just prior to assessment, the increased pulse rate would not add to the score.

<table>
<thead>
<tr>
<th>Enter scores at time zero, 30 minutes after first dose, 2 hours after first dose, etc.</th>
<th>Time:</th>
<th>Time:</th>
<th>Time:</th>
<th>Time:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Resting Pulse Rate:</strong> Record beats per minute after patient is sitting or lying down for one minute</td>
<td>0 - pulse rate 80 or below</td>
<td>2 - pulse rate 101–120</td>
<td>4 - pulse rate greater than 120</td>
<td></td>
</tr>
<tr>
<td>1 - pulse rate 81–100</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sweating:</strong> Over past ½ hour not accounted for by room temperature or activity</td>
<td>0 - no chills or flushing</td>
<td>3 - beads of sweat on brow or face</td>
<td>4 - sweat streaming off face</td>
<td></td>
</tr>
<tr>
<td>1 - subjective chills or flushing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 - flushed or observable moistness on face</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restlessness:</strong> Observation during assessment</td>
<td>3 - frequent shifting or extraneous movement of legs/arms</td>
<td>5 - unable to sit still for more than a few seconds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 - able to sit still</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 - reports difficulty sitting still, but is able to do so</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pupil size</strong></td>
<td>2 - pupils moderately dilated</td>
<td>5 - pupils dilated that only rim of the iris is visible</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 - pupils pinned or normal size for light</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 - pupils possibly larger than normal for light</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bone or joint aches:</strong> If patient was having pain previously, only the additional component attributed to opiate withdrawal is scored</td>
<td>4 - patient is rubbing joints or muscles and is unable to sit still because of discomfort</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 - not present</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 - mild/diffuse discomfort</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 - patient reports severe diffuse aching of joints/muscles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Runny nose or tearing:</strong> Not accounted for by cold symptoms or allergy</td>
<td>2 - nose running or tearing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 - none present</td>
<td>3 - nose constantly running or tears streaming down cheeks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 - nasal stuffiness or unusually moist eyes</td>
<td>4 - nose running or tearing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GI upset:</strong> Over last ½ hour</td>
<td>2 - nausea or loose stool</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 - no GI symptoms</td>
<td>3 - vomiting or diarrhea</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 - stomach cramps</td>
<td>5 - multiple episodes of diarrhea or vomiting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tremor:</strong> Observation of outstretched hands</td>
<td>2 - slight tremor observable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 - no tremor</td>
<td>4 - gross tremor or muscle twitching</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 - tremor can be felt, but not observed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Yawning:</strong> Observation during assessment</td>
<td>2 - yawning three or more times during assessment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 - no yawning</td>
<td>4 - yawning several times/minute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 - yawning once or twice during assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anxiety or irritability</strong></td>
<td>2 - patient obviously irritable or anxious</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 - none</td>
<td>4 - patient so irritable or anxious that participation in the assessment is difficult</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 - patient reports increasing irritability or anxiousness</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gooseflesh skin</strong></td>
<td>3 - piloerrection of skin can be felt or hairs standing up on arms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 - skin is smooth</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 - prominent piloerrection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5—12 = mild; 13—24 = moderate; 25—36 = moderately severe; > 36 = severe withdrawal

**Observer Initials**

---

## Appendix B – Non-Pregnancy Decision Guide

<table>
<thead>
<tr>
<th><strong>Methadone</strong></th>
<th><strong>Buprenorphine</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism</strong></td>
<td>Full opioid agonist</td>
</tr>
<tr>
<td><strong>Patients for whom should use caution or avoid</strong></td>
<td>Allergy, severe liver disease, QTc prolongation, drug-drug interactions, high risk job</td>
</tr>
<tr>
<td><strong>Risk of withdrawal when starting medication</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Side effects/risks</strong></td>
<td>Hypogonadism, Torsades, constipation, sweating</td>
</tr>
<tr>
<td><strong>Sedation/respiratory depression</strong></td>
<td>At high doses in non-tolerant patients or slow metabolizers has potential for sedation, worse in combination with some medications</td>
</tr>
<tr>
<td><strong>Overdose risk from opioid replacement</strong></td>
<td>Low-moderate, higher when initiating treatment or in combo with other medications</td>
</tr>
<tr>
<td><strong>Retention in treatment</strong></td>
<td>Higher in methadone, with possible contribution from increased structure of programs</td>
</tr>
<tr>
<td><strong>Visit frequency</strong></td>
<td>Daily visits to maintenance treatment program, take-homes may be allowed if stable for long term. This structure helps some patients, some dislike it.</td>
</tr>
<tr>
<td><strong>Diversion potential</strong></td>
<td>Low for directly observed therapy (DOT), high for take home</td>
</tr>
<tr>
<td><strong>Who can prescribe after discharge?</strong></td>
<td>Opioid treatment program only</td>
</tr>
<tr>
<td><strong>Mortality</strong></td>
<td>Both options substantially decrease all-cause mortality over no treatment, methadone may have higher mortality but may be confounded</td>
</tr>
</tbody>
</table>

Some patients may decline buprenorphine or methadone, but still be interested in medication assisted treatment. In these cases, one option is naltrexone, however it has been shown to have very high drop-out rates so is not considered first line. Naltrexone can only be started after a patient has completely withdrawn from opioids—roughly 5-7 day for short acting and 7-10 days for long acting. One option is to give naloxone as a trial before administering naltrexone, to make sure the patient doesn’t experience precipitated withdrawal. Dosing usually begins with 25mg on the first day, and is then increased to 50 mg daily. For IM formulation, the dose is usually 380 mg q4 weeks. The most common side effects are nausea, vomiting, and headache.

---

### Inpatient Management of Opioid Use Disorder: Methadone

#### Appendix C– Pregnancy Decision Guide

<table>
<thead>
<tr>
<th></th>
<th>Methadone</th>
<th>Buprenorphine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mechanism</strong></td>
<td>Full opioid agonist</td>
<td>Partial opioid agonist, usually paired with naloxone (opioid antagonist)</td>
</tr>
<tr>
<td><strong>Patients for whom use caution or avoid</strong></td>
<td>Allergy, severe liver disease, QTc prolongation, drug-drug interactions, high risk job</td>
<td>Allergy, severe liver disease, heavy ETOH or benzo, need for acute opioids, recent methadone</td>
</tr>
<tr>
<td><strong>Risk of withdrawal when starting medication</strong></td>
<td>None</td>
<td>Some, if not in withdrawal prior to starting may have precipitated withdrawal</td>
</tr>
<tr>
<td><strong>Side effects/risks</strong></td>
<td>Hypogonadism, Torsades, constipation, sweating</td>
<td>GI upset, constipation, headache, insomnia</td>
</tr>
<tr>
<td><strong>Sedation/respiratory depression</strong></td>
<td>At high doses in non-tolerant patients or slow metabolizers has potential for sedation, worse in combination with some medications</td>
<td>Ceiling effect for respiratory depression therefore less risky (unless concurrent use of sedating drugs, e.g., alcohol/benzodiazepines)</td>
</tr>
<tr>
<td><strong>Overdose risk from opioid replacement</strong></td>
<td>Low-moderate, higher when initiating treatment or in combo with other medications</td>
<td>Low, increased by concurrent sedating medications</td>
</tr>
<tr>
<td><strong>Retention in treatment</strong></td>
<td>Higher in methadone (88% in the MOTHER study), with possible contribution from increased structure of programs</td>
<td>Slightly lower than methadone (67% in the MOTHER study, with most drop outs during induction)</td>
</tr>
<tr>
<td><strong>Visit frequency</strong></td>
<td>Daily visits to maintenance treatment program, take-homes may be allowed if stable for long term. This structure helps some patients, some dislike it.</td>
<td>Can range from daily to monthly depending on patient treatment needs, may be provided in primary care setting. Also available in some methadone clinics, increasing structure and decreasing diversion risk.</td>
</tr>
<tr>
<td><strong>Diversion potential</strong></td>
<td>Low for directly observed therapy (DOT), high for take home</td>
<td>Low for DOT, moderate for take-homes, reduced by co-formulation with naloxone</td>
</tr>
<tr>
<td><strong>Who can prescribe after discharge?</strong></td>
<td>Opioid treatment program only</td>
<td>Any physician, NP, or PA who has been trained and possesses DATA2000 waivers (aka X-number)</td>
</tr>
<tr>
<td><strong>Mortality</strong></td>
<td>Both options substantially decrease all-cause mortality over no treatment, methadone may have higher mortality but may be confounded⁴</td>
<td>Both options substantially decrease all-cause mortality over no treatment, buprenorphine may have lower mortality but may be confounded</td>
</tr>
<tr>
<td><strong>Neonatal Outcomes⁴</strong></td>
<td>Reduced preterm birth and low birth weight rates Higher doses do NOT correlate with more NAS NAS is 75% - in MOTHER study: 17.5 day average length of hospitalization 10.4 mg morphine required during hospitalization</td>
<td>Reduced preterm birth and low birth weight rates Later average gestational age and higher average birth weight than methadone Higher doses do NOT correlate with more NAS NAS less severe than for methadone – in MOTHER study: 10 day average length of hospitalization 1.1 mg morphine required during hospitalization</td>
</tr>
</tbody>
</table>

Naltrexone is not a good option in pregnancy due to safety concerns

---